Disease · MONDO_0015075

thyroid gland carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. thyroid gland carcinoma. Diseases, record MONDO_0015075. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015075

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: thyroid gland carcinoma; Open Targets
Open Targets ID: MONDO_0015075; Open Targets
Other names: cancer of the thyroid, cancer of thyroid, carcinoma of the thyroid, carcinoma of the thyroid gland, carcinoma of thyroid, carcinoma of thyroid gland, head and neck cancer, thyroid, thyroid cancer, thyroid carcinoma, thyroid gland cancer; Open Targets
Disease Ontology: DOID:3963; Disease Ontology
NCI Thesaurus: C4815; NCI Thesaurus
Orphanet: ORPHA:100088; Orphanet
Highest stage of its drugs: Approval, for 7 of its 63 drugs, from DailyMed and FDA; Open Targets

Drugs63

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
SODIUM IODIDE I 131	CHEMBL1201084	Small molecule	Approval	DailyMed and FDA	3	1	0	Drugs and targets
LENVATINIB MESYLATE	CHEMBL2105704	Small molecule	Approval	DailyMed and FDA	2	0	0	Drugs and targets
CABOZANTINIB S-MALATE	CHEMBL2103868	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LEVOTHYROXINE SODIUM	CHEMBL2103741	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
SORAFENIB TOSYLATE	CHEMBL1200485	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
THYROTROPIN ALFA	CHEMBL1201533	Protein	Approval	DailyMed	1	0	0	Drugs and targets
VANDETANIB	CHEMBL24828	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
TRAMETINIB	CHEMBL2103875	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 63

See all 63 drugs

Targets108

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	11	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	9	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2324	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	8	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/2321	Drugs and targets
RET	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET	7	Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor	Approval	https://conductscience.org/library/genes/5979	Drugs and targets
EGFR	Epidermal growth factor receptor	5	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
ERBB2	Epidermal growth factor receptor	5	Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor	Approval	https://conductscience.org/library/genes/2064	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/3815	Drugs and targets
PDCD1	Programmed cell death protein 1	5	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	5	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/5159	Drugs and targets
ALK	ALK tyrosine kinase receptor	4	ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor	Phase 2	https://conductscience.org/library/genes/238	Drugs and targets

1 to 10 of 108

See all 108 targets

Trials17

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03037385	Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/2	590	2025-05-31	RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, RET-altered Colon Cancer, RET-altered Solid Tumors, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung, Thyroid Diseases, Thyroid Neoplasm, Thyroid Cancer, Papillary, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasm, Head and Neck Neoplasms, Adenocarcinoma, Papillary, Adenocarcinoma, Carcinoma, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Colonic Neoplasms, Colorectal Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasm, Digestive System Disease, Gastrointestinal Disease, Colonic Diseases, Intestinal Disease	PRALSETINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT03753919	Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial	Phase 2	79	2026-03-11	Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00098813	Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine	Phase 2	20	2013-12-19	Recurrent Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer	ROMIDEPSIN	Its record names the disease	ClinicalTrials.gov
NCT04462471	Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers	Phase 1	8	2025-02-28	Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell), Thyroid Cancer, Papillary, BRAF V600E Mutation Positive	COPANLISIB, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT01655719	Pioglitazone in Thyroid Cancers	Phase 2	1	2017-10-26	Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene	PIOGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT02925234	The Drug Rediscovery Protocol (DRUP Trial)	Phase 2	1,550		Cancer, Tumors, Neoplasm, Neoplasia	ABEMACICLIB, AFATINIB, ALECTINIB, ALPELISIB, ATEZOLIZUMAB, AXITINIB, BEVACIZUMAB, CABOZANTINIB, CRIZOTINIB, DABRAFENIB, DACOMITINIB ANHYDROUS, DURVALUMAB, ENTRECTINIB, ERDAFITINIB, ERLOTINIB, IPILIMUMAB, LENVATINIB, LORLATINIB, NILOTINIB, NIRAPARIB, NIVOLUMAB, OLAPARIB, PALBOCICLIB, PANITUMUMAB, PEMBROLIZUMAB, PEMIGATINIB, PERTUZUMAB, REGORAFENIB, RIBOCICLIB, RUCAPARIB, SELPERCATINIB, SUNITINIB, TALAZOPARIB, TEPOTINIB, TRAMETINIB, TRASTUZUMAB, VISMODEGIB	Its record names the disease	ClinicalTrials.gov
NCT05275374	XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation	Phase 1/2	221		Cancer, BRAF V600 Mutation, Melanoma, Colorectal Cancer, Thyroid Cancer, Nonsmall Cell Lung Cancer	TRAMETINIB, XP-102	Its record names the disease	ClinicalTrials.gov
NCT04742959	Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors	Phase 1/2	203		Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer	TINENGOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03360890	Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors	Phase 2	46		Thyroid Cancer, Salivary Gland Cancer	DOCETAXEL, PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03387943	PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma	Phase 2	30		Poorly Differentiated Thyroid Carcinoma	CISPLATIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 17

See all 17 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials21

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41986720	DERIVED	1	PubMed
41935063	DERIVED	1	PubMed
41886723	DERIVED	1	PubMed
40639400	DERIVED	1	PubMed
38630551	DERIVED	1	PubMed
38471288	DERIVED	1	PubMed
38009200	DERIVED	1	PubMed
37934000	DERIVED	1	PubMed
37916501	DERIVED	1	PubMed
37424386	DERIVED	1	PubMed

1 to 10 of 21

See all 21 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0015075

GET https://conductscience.org/api/diseases/v1/MONDO_0015075/drugs?page=2

API reference For AI assistants